Actinium Pharmaceuticals, Inc. Quarterly Common Stock, Shares Authorized from Q4 2010 to Q3 2024

Taxonomy & unit
us-gaap: shares
Description
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Summary
Actinium Pharmaceuticals, Inc. quarterly Common Stock, Shares Authorized history and growth rate from Q4 2010 to Q3 2024.
  • Actinium Pharmaceuticals, Inc. Common Stock, Shares Authorized for the quarter ending September 30, 2024 was 1B shares, unchanged year-over-year.
Common Stock, Shares Authorized, Quarterly (shares)
Common Stock, Shares Authorized, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 1B 0 0% Sep 30, 2024 10-Q 2024-11-14
Q2 2024 1B 0 0% Jun 30, 2024 10-Q 2024-08-05
Q1 2024 1B 0 0% Mar 31, 2024 10-Q 2024-04-26
Q4 2023 1B 0 0% Dec 31, 2023 10-Q 2024-11-14
Q3 2023 1B 0 0% Sep 30, 2023 10-Q 2023-11-02
Q2 2023 1B 0 0% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 1B 0 0% Mar 31, 2023 10-Q 2023-05-15
Q4 2022 1B 0 0% Dec 31, 2022 10-K 2024-03-29
Q3 2022 1B 0 0% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 1B 0 0% Jun 30, 2022 10-Q 2022-08-12
Q1 2022 1B 0 0% Mar 31, 2022 10-Q 2022-05-13
Q4 2021 1B +400M +66.7% Dec 31, 2021 10-K 2023-03-31
Q3 2021 1B 0 0% Sep 30, 2021 10-Q 2021-11-12
Q2 2021 1B 0 0% Jun 30, 2021 10-Q 2021-07-30
Q1 2021 1B 0 0% Mar 31, 2021 10-Q 2021-05-14
Q4 2020 600M -400M -40% Dec 31, 2020 10-K 2022-03-25
Q3 2020 1B +400M +66.7% Sep 30, 2020 10-Q 2020-10-23
Q2 2020 1B +400M +66.7% Jun 30, 2020 10-Q 2020-08-14
Q1 2020 1B +400M +66.7% Mar 31, 2020 10-Q 2020-06-30
Q4 2019 1B +400M +66.7% Dec 31, 2019 10-K 2021-03-31
Q3 2019 600M +200M +50% Sep 30, 2019 10-Q 2019-11-12
Q2 2019 600M +200M +50% Jun 30, 2019 10-Q 2019-08-09
Q1 2019 600M +200M +50% Mar 31, 2019 10-Q 2019-05-10
Q4 2018 600M +200M +50% Dec 31, 2018 10-K 2020-05-08
Q3 2018 400M +200M +100% Sep 30, 2018 10-Q 2018-11-09
Q2 2018 400M +200M +100% Jun 30, 2018 10-Q 2018-08-09
Q1 2018 400M +200M +100% Mar 31, 2018 10-Q 2018-05-10
Q4 2017 400M 0 0% Dec 31, 2017 10-K 2019-03-15
Q3 2017 200M 0 0% Sep 30, 2017 10-Q 2017-11-03
Q2 2017 200M 0 0% Jun 30, 2017 10-Q 2017-08-04
Q1 2017 200M 0 0% Mar 31, 2017 10-Q 2017-05-15
Q4 2016 400M +200M +100% Dec 31, 2016 10-K 2018-03-16
Q3 2016 200M 0 0% Sep 30, 2016 10-Q 2016-10-28
Q2 2016 200M 0 0% Jun 30, 2016 10-Q 2016-07-29
Q1 2016 200M 0 0% Mar 31, 2016 10-Q 2016-05-10
Q4 2015 200M 0 0% Dec 31, 2015 10-K 2017-03-16
Q3 2015 200M 0 0% Sep 30, 2015 10-Q 2015-10-30
Q2 2015 200M +100M +100% Jun 30, 2015 10-Q 2015-08-07
Q1 2015 200M 0 0% Mar 31, 2015 10-Q 2015-05-08
Q4 2014 200M 0 0% Dec 31, 2014 10-K 2016-03-11
Q3 2014 200M +100M +100% Sep 30, 2014 10-Q 2014-10-31
Q2 2014 100M 0 0% Jun 30, 2014 10-Q 2014-08-12
Q1 2014 200M +100M +100% Mar 31, 2014 10-Q 2014-05-12
Q4 2013 200M 0 0% Dec 31, 2013 10-K 2015-03-16
Q3 2013 100M 0 0% Sep 30, 2013 10-Q 2013-11-14
Q2 2013 100M 0 0% Jun 30, 2013 10-Q 2013-08-13
Q1 2013 100M 0 0% Mar 31, 2013 10-Q 2013-05-15
Q4 2012 200M +100M +100% Dec 31, 2012 10-K 2014-02-28
Q3 2012 100M 0 0% Sep 30, 2012 10-Q 2012-11-14
Q2 2012 100M 0 0% Jun 30, 2012 10-Q/A 2012-08-29
Q1 2012 100M Mar 31, 2012 10-Q 2012-04-23
Q4 2011 100M 0 0% Dec 31, 2011 10-K 2013-03-29
Q3 2011 100M Sep 30, 2011 10-Q 2011-11-14
Q2 2011 100M Jun 30, 2011 10-Q 2011-08-12
Q4 2010 100M Dec 31, 2010 10-K 2012-04-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.